ClostraBio is a biopharma company developing therapeutics for food allergies.
ClostraBio has raised $4.0M in total funding. The most recent round was Series A. The last funding was announced in September 2022.
ClostraBio's investors include University of Chicago, Portal Innovations, Joseph Mansueto.
ClostraBio is headquartered in Chicago, United States.
ClostraBio is a biopharma company developing therapeutics for food allergies.
ClostraBio is at the Series A stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"ClostraBio — Funding & Investors." VCBacked, September 30, 2022, https://www.vcbacked.co/company/clostrabio. Accessed September 30, 2026.
VCBacked. (2022). ClostraBio — Funding & Investors. Retrieved September 30, 2026, from https://www.vcbacked.co/company/clostrabio
{{cite web |title=ClostraBio — Funding & Investors |url=https://www.vcbacked.co/company/clostrabio |website=VCBacked |access-date=September 30, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated